West Virginia MPJE (Pharmacy Jurisprudence) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the West Virginia MPJE Exam. Includes flashcards and multiple-choice questions, each with hints and explanations. Prepare effectively for your pharmacy law exam!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.


Which sale under the Combat Methamphetamine Epidemic Act does not require documentation?

  1. Purchase of 60 mg of ephedrine in any form

  2. Purchase of single dose packet of pseudoephedrine containing a maximum of 60 mg

  3. Purchase of phenylpropanolamine in any quantity

  4. Purchase of pseudoephedrine in any form

The correct answer is: Purchase of 60 mg of ephedrine in any form

The correct answer is based on the provisions established by the Combat Methamphetamine Epidemic Act, which regulates the sale of products containing pseudoephedrine and other precursors used in the illicit manufacture of methamphetamine. Under this law, the purchase of 60 mg of ephedrine in any form does not require documentation because small purchases, specifically those under 60 mg, are exempt from the record-keeping requirements that apply to larger quantities of pseudoephedrine and other designated products. This regulatory framework focuses on preventing misuse while allowing consumers convenient access to certain medications. In contrast, the other options involve regulatory guidelines that require documentation. For example, purchases of pseudoephedrine, whether in single doses or different quantities, mandate that sellers maintain logs documenting the purchaser's information. This is necessary to track sales and prevent large-scale purchases that might contribute to illegal manufacturing activities. Thus, while larger quantities and certain formulations require strict documentation protocols, the purchase of a minimal amount of ephedrine not exceeding 60 mg is treated differently to encourage safe consumer access without the same regulatory burden.